Arbutus Biopharma Corp
NASDAQ:ABUS
Intrinsic Value
Arbutus Biopharma Corp. is a biopharmaceutical company. [ Read More ]
The intrinsic value of one ABUS stock under the Base Case scenario is 0.82 USD. Compared to the current market price of 2.73 USD, Arbutus Biopharma Corp is Overvalued by 70%.
Valuation Backtest
Arbutus Biopharma Corp
Run backtest to discover the historical profit from buying and selling ABUS stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Arbutus Biopharma Corp
Current Assets | 132m |
Cash & Short-Term Investments | 126m |
Receivables | 1.8m |
Other Current Assets | 4.2m |
Non-Current Assets | 12.4m |
Long-Term Investments | 6.3m |
PP&E | 6.1m |
Current Liabilities | 22.5m |
Accounts Payable | 3.2m |
Accrued Liabilities | 7.5m |
Other Current Liabilities | 11.8m |
Non-Current Liabilities | 15.9m |
Other Non-Current Liabilities | 15.9m |
Earnings Waterfall
Arbutus Biopharma Corp
Revenue
|
18.1m
USD
|
Operating Expenses
|
-96.2m
USD
|
Operating Income
|
-78.1m
USD
|
Other Expenses
|
5.3m
USD
|
Net Income
|
-72.8m
USD
|
Free Cash Flow Analysis
Arbutus Biopharma Corp
What is Free Cash Flow?
ABUS Profitability Score
Profitability Due Diligence
Arbutus Biopharma Corp's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Arbutus Biopharma Corp's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
ABUS Solvency Score
Solvency Due Diligence
Arbutus Biopharma Corp's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Score
Arbutus Biopharma Corp's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ABUS Price Targets Summary
Arbutus Biopharma Corp
According to Wall Street analysts, the average 1-year price target for ABUS is 4.49 USD with a low forecast of 4.04 USD and a high forecast of 5.25 USD.
Ownership
ABUS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ABUS Price
Arbutus Biopharma Corp
Average Annual Return | -4.37% |
Standard Deviation of Annual Returns | 29.19% |
Max Drawdown | -73% |
Market Capitalization | 463.7m USD |
Shares Outstanding | 180 175 008 |
Percentage of Shares Shorted | 3.3% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Arbutus Biopharma Corp. is a biopharmaceutical company. The company is headquartered in Warminster, Pennsylvania and currently employs 85 full-time employees. The company went IPO on 2010-11-13. The firm is focused on virology capabilities to develop therapeutics that target specific viral diseases. The Company’s focus areas include Hepatitis B virus (HBV), SARS-CoV-2 and other coronaviruses. In HBV, the Company is developing a ribonucleic acid interference (RNAi) therapeutic, oral capsid inhibitor, an oral PD-L1 inhibitor, and oral RNA destabilizer that it intends to combine to provide a functional cure for patients with chronic HBV infection (cHBV) by suppressing viral replication, reducing surface antigen and reawakening the immune system. Its lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening and is being evaluated in multiple Phase II clinical trials. The firm is having an ongoing drug discovery and development program directed at identifying orally active agents for treating coronaviruses (including SARS-CoV-2).
Contact
IPO
Employees
Officers
The intrinsic value of one ABUS stock under the Base Case scenario is 0.82 USD.
Compared to the current market price of 2.73 USD, Arbutus Biopharma Corp is Overvalued by 70%.